Etiological Aspects for the Occurrence of Diabetic Neuropathy and the Suggested Measures
Diabetic neuropathy is a painful devitalizing complication of diabetes affecting almost 20% individuals with this disease. Based on the area where neurons are mostly affected, it is categorized into four different types, proximal, peripheral, autonomic, and focal, and each type shows varying symptom...
Gespeichert in:
Veröffentlicht in: | Neurophysiology (New York) 2020-03, Vol.52 (2), p.159-168 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 168 |
---|---|
container_issue | 2 |
container_start_page | 159 |
container_title | Neurophysiology (New York) |
container_volume | 52 |
creator | Grover, M. Makkar, R. Sehgal, A. Seth, S. K. Gupta, J. Behl, T. |
description | Diabetic neuropathy is a painful devitalizing complication of diabetes affecting almost 20% individuals with this disease. Based on the area where neurons are mostly affected, it is categorized into four different types, proximal, peripheral, autonomic, and focal, and each type shows varying symptoms like numbness, gastric problems, heart problems, etc. Sometimes, these symptoms are mistakenly taken as those of gastric disorders, heart attack, or arrhythmia, with paying no attention to the inflamed neuronal supply in the particular area. Despite being aware of the symptoms, it is still a major challenging task for concerned endocrinologists and neurologists to diagnose it among the participants in clinics or in clinical trials. Treatment of diabetic neuropathy involves three major approaches, maintenance of the sugar level, pathogenetic treatment, and relieve of pain. Certain recommended drugs for pain relief are antidepressants (like duloxetine), GABA analogs (like gabapentin or pregabalin), and some other proposed treatments under research (like α-lipoic acid, aldose reductase inhibitors, or benfoitamine). The current drugs which are being provided for this disease are all indirectly acting and doesn’t have any direct action on the neuronal part. So, currently the need for today is to provide most potent drugs or combination of drugs to relieve the pain of diabetic neuropathy individuals by acting directly on the nerves without laying any side effects. |
doi_str_mv | 10.1007/s11062-020-09865-2 |
format | Article |
fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_2450779271</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A640620813</galeid><sourcerecordid>A640620813</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-28de356ffe983083a03e18224b0bd817a3634d36333396259d0e24869fcf0b33</originalsourceid><addsrcrecordid>eNp9kU1rXCEUhiW0kGmaP5CV0FUXd3rU-6HLIU3bwDSBJIvsxPEe7xhmrlP1Qubf12QKYaBEQUGf5_jxEnLBYM4Aum-JMWh5BRwqULJtKn5CZqzpRKXK9gcyA1BQcdV1p-RTSk8A0ErVzMjjVfZhEwZvzYYu0g5tTtSFSPMa6a21U4w4WqTB0e_erDB7S29wimFn8npPzdi_kvfTMGDK2NPfaNIUMX0mH53ZJDz_N5-Rhx9XD5e_quXtz-vLxbKyNYdccdmjaFrnUEkBUhgQyCTn9QpWvWSdEa2o-zKUplreqB6Q17JVzjpYCXFGvhzK7mL4M5Ur6KcwxbGcqHndQNcp3rE3ajAb1H50IUdjtz5ZvWjr8nMg2Uut-X-o0nvcehtGdL6sHwlfj4TCZHzOg5lS0tf3d8csP7A2hpQiOr2LfmviXjPQLxnqQ4a6ZKhfM9S8SOIgpQKPA8a3171j_QXyPpsq</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2450779271</pqid></control><display><type>article</type><title>Etiological Aspects for the Occurrence of Diabetic Neuropathy and the Suggested Measures</title><source>SpringerLink Journals - AutoHoldings</source><creator>Grover, M. ; Makkar, R. ; Sehgal, A. ; Seth, S. K. ; Gupta, J. ; Behl, T.</creator><creatorcontrib>Grover, M. ; Makkar, R. ; Sehgal, A. ; Seth, S. K. ; Gupta, J. ; Behl, T.</creatorcontrib><description>Diabetic neuropathy is a painful devitalizing complication of diabetes affecting almost 20% individuals with this disease. Based on the area where neurons are mostly affected, it is categorized into four different types, proximal, peripheral, autonomic, and focal, and each type shows varying symptoms like numbness, gastric problems, heart problems, etc. Sometimes, these symptoms are mistakenly taken as those of gastric disorders, heart attack, or arrhythmia, with paying no attention to the inflamed neuronal supply in the particular area. Despite being aware of the symptoms, it is still a major challenging task for concerned endocrinologists and neurologists to diagnose it among the participants in clinics or in clinical trials. Treatment of diabetic neuropathy involves three major approaches, maintenance of the sugar level, pathogenetic treatment, and relieve of pain. Certain recommended drugs for pain relief are antidepressants (like duloxetine), GABA analogs (like gabapentin or pregabalin), and some other proposed treatments under research (like α-lipoic acid, aldose reductase inhibitors, or benfoitamine). The current drugs which are being provided for this disease are all indirectly acting and doesn’t have any direct action on the neuronal part. So, currently the need for today is to provide most potent drugs or combination of drugs to relieve the pain of diabetic neuropathy individuals by acting directly on the nerves without laying any side effects.</description><identifier>ISSN: 0090-2977</identifier><identifier>EISSN: 1573-9007</identifier><identifier>DOI: 10.1007/s11062-020-09865-2</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Aldehyde reductase ; Aldose reductase ; Analgesics ; Antidepressants ; Arrhythmia ; Autonomic nervous system ; Biomedical and Life Sciences ; Biomedicine ; Clinical trials ; Development and progression ; Diabetes ; Diabetes mellitus ; Diabetic neuropathies ; Diabetic neuropathy ; Drugs ; Duloxetine ; Gabapentin ; Gastrointestinal diseases ; Heart attack ; Inflammation ; Lipoic acid ; Myocardial infarction ; Nerves ; Neurosciences ; Pain ; Polyols ; Type 2 diabetes ; γ-Aminobutyric acid</subject><ispartof>Neurophysiology (New York), 2020-03, Vol.52 (2), p.159-168</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020</rights><rights>COPYRIGHT 2020 Springer</rights><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-28de356ffe983083a03e18224b0bd817a3634d36333396259d0e24869fcf0b33</citedby><cites>FETCH-LOGICAL-c420t-28de356ffe983083a03e18224b0bd817a3634d36333396259d0e24869fcf0b33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11062-020-09865-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11062-020-09865-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids></links><search><creatorcontrib>Grover, M.</creatorcontrib><creatorcontrib>Makkar, R.</creatorcontrib><creatorcontrib>Sehgal, A.</creatorcontrib><creatorcontrib>Seth, S. K.</creatorcontrib><creatorcontrib>Gupta, J.</creatorcontrib><creatorcontrib>Behl, T.</creatorcontrib><title>Etiological Aspects for the Occurrence of Diabetic Neuropathy and the Suggested Measures</title><title>Neurophysiology (New York)</title><addtitle>Neurophysiology</addtitle><description>Diabetic neuropathy is a painful devitalizing complication of diabetes affecting almost 20% individuals with this disease. Based on the area where neurons are mostly affected, it is categorized into four different types, proximal, peripheral, autonomic, and focal, and each type shows varying symptoms like numbness, gastric problems, heart problems, etc. Sometimes, these symptoms are mistakenly taken as those of gastric disorders, heart attack, or arrhythmia, with paying no attention to the inflamed neuronal supply in the particular area. Despite being aware of the symptoms, it is still a major challenging task for concerned endocrinologists and neurologists to diagnose it among the participants in clinics or in clinical trials. Treatment of diabetic neuropathy involves three major approaches, maintenance of the sugar level, pathogenetic treatment, and relieve of pain. Certain recommended drugs for pain relief are antidepressants (like duloxetine), GABA analogs (like gabapentin or pregabalin), and some other proposed treatments under research (like α-lipoic acid, aldose reductase inhibitors, or benfoitamine). The current drugs which are being provided for this disease are all indirectly acting and doesn’t have any direct action on the neuronal part. So, currently the need for today is to provide most potent drugs or combination of drugs to relieve the pain of diabetic neuropathy individuals by acting directly on the nerves without laying any side effects.</description><subject>Aldehyde reductase</subject><subject>Aldose reductase</subject><subject>Analgesics</subject><subject>Antidepressants</subject><subject>Arrhythmia</subject><subject>Autonomic nervous system</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Clinical trials</subject><subject>Development and progression</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetic neuropathies</subject><subject>Diabetic neuropathy</subject><subject>Drugs</subject><subject>Duloxetine</subject><subject>Gabapentin</subject><subject>Gastrointestinal diseases</subject><subject>Heart attack</subject><subject>Inflammation</subject><subject>Lipoic acid</subject><subject>Myocardial infarction</subject><subject>Nerves</subject><subject>Neurosciences</subject><subject>Pain</subject><subject>Polyols</subject><subject>Type 2 diabetes</subject><subject>γ-Aminobutyric acid</subject><issn>0090-2977</issn><issn>1573-9007</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kU1rXCEUhiW0kGmaP5CV0FUXd3rU-6HLIU3bwDSBJIvsxPEe7xhmrlP1Qubf12QKYaBEQUGf5_jxEnLBYM4Aum-JMWh5BRwqULJtKn5CZqzpRKXK9gcyA1BQcdV1p-RTSk8A0ErVzMjjVfZhEwZvzYYu0g5tTtSFSPMa6a21U4w4WqTB0e_erDB7S29wimFn8npPzdi_kvfTMGDK2NPfaNIUMX0mH53ZJDz_N5-Rhx9XD5e_quXtz-vLxbKyNYdccdmjaFrnUEkBUhgQyCTn9QpWvWSdEa2o-zKUplreqB6Q17JVzjpYCXFGvhzK7mL4M5Ur6KcwxbGcqHndQNcp3rE3ajAb1H50IUdjtz5ZvWjr8nMg2Uut-X-o0nvcehtGdL6sHwlfj4TCZHzOg5lS0tf3d8csP7A2hpQiOr2LfmviXjPQLxnqQ4a6ZKhfM9S8SOIgpQKPA8a3171j_QXyPpsq</recordid><startdate>20200301</startdate><enddate>20200301</enddate><creator>Grover, M.</creator><creator>Makkar, R.</creator><creator>Sehgal, A.</creator><creator>Seth, S. K.</creator><creator>Gupta, J.</creator><creator>Behl, T.</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>7TK</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20200301</creationdate><title>Etiological Aspects for the Occurrence of Diabetic Neuropathy and the Suggested Measures</title><author>Grover, M. ; Makkar, R. ; Sehgal, A. ; Seth, S. K. ; Gupta, J. ; Behl, T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-28de356ffe983083a03e18224b0bd817a3634d36333396259d0e24869fcf0b33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Aldehyde reductase</topic><topic>Aldose reductase</topic><topic>Analgesics</topic><topic>Antidepressants</topic><topic>Arrhythmia</topic><topic>Autonomic nervous system</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Clinical trials</topic><topic>Development and progression</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetic neuropathies</topic><topic>Diabetic neuropathy</topic><topic>Drugs</topic><topic>Duloxetine</topic><topic>Gabapentin</topic><topic>Gastrointestinal diseases</topic><topic>Heart attack</topic><topic>Inflammation</topic><topic>Lipoic acid</topic><topic>Myocardial infarction</topic><topic>Nerves</topic><topic>Neurosciences</topic><topic>Pain</topic><topic>Polyols</topic><topic>Type 2 diabetes</topic><topic>γ-Aminobutyric acid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Grover, M.</creatorcontrib><creatorcontrib>Makkar, R.</creatorcontrib><creatorcontrib>Sehgal, A.</creatorcontrib><creatorcontrib>Seth, S. K.</creatorcontrib><creatorcontrib>Gupta, J.</creatorcontrib><creatorcontrib>Behl, T.</creatorcontrib><collection>CrossRef</collection><collection>Gale In Context: Science</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Neurophysiology (New York)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Grover, M.</au><au>Makkar, R.</au><au>Sehgal, A.</au><au>Seth, S. K.</au><au>Gupta, J.</au><au>Behl, T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Etiological Aspects for the Occurrence of Diabetic Neuropathy and the Suggested Measures</atitle><jtitle>Neurophysiology (New York)</jtitle><stitle>Neurophysiology</stitle><date>2020-03-01</date><risdate>2020</risdate><volume>52</volume><issue>2</issue><spage>159</spage><epage>168</epage><pages>159-168</pages><issn>0090-2977</issn><eissn>1573-9007</eissn><abstract>Diabetic neuropathy is a painful devitalizing complication of diabetes affecting almost 20% individuals with this disease. Based on the area where neurons are mostly affected, it is categorized into four different types, proximal, peripheral, autonomic, and focal, and each type shows varying symptoms like numbness, gastric problems, heart problems, etc. Sometimes, these symptoms are mistakenly taken as those of gastric disorders, heart attack, or arrhythmia, with paying no attention to the inflamed neuronal supply in the particular area. Despite being aware of the symptoms, it is still a major challenging task for concerned endocrinologists and neurologists to diagnose it among the participants in clinics or in clinical trials. Treatment of diabetic neuropathy involves three major approaches, maintenance of the sugar level, pathogenetic treatment, and relieve of pain. Certain recommended drugs for pain relief are antidepressants (like duloxetine), GABA analogs (like gabapentin or pregabalin), and some other proposed treatments under research (like α-lipoic acid, aldose reductase inhibitors, or benfoitamine). The current drugs which are being provided for this disease are all indirectly acting and doesn’t have any direct action on the neuronal part. So, currently the need for today is to provide most potent drugs or combination of drugs to relieve the pain of diabetic neuropathy individuals by acting directly on the nerves without laying any side effects.</abstract><cop>New York</cop><pub>Springer US</pub><doi>10.1007/s11062-020-09865-2</doi><tpages>10</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0090-2977 |
ispartof | Neurophysiology (New York), 2020-03, Vol.52 (2), p.159-168 |
issn | 0090-2977 1573-9007 |
language | eng |
recordid | cdi_proquest_journals_2450779271 |
source | SpringerLink Journals - AutoHoldings |
subjects | Aldehyde reductase Aldose reductase Analgesics Antidepressants Arrhythmia Autonomic nervous system Biomedical and Life Sciences Biomedicine Clinical trials Development and progression Diabetes Diabetes mellitus Diabetic neuropathies Diabetic neuropathy Drugs Duloxetine Gabapentin Gastrointestinal diseases Heart attack Inflammation Lipoic acid Myocardial infarction Nerves Neurosciences Pain Polyols Type 2 diabetes γ-Aminobutyric acid |
title | Etiological Aspects for the Occurrence of Diabetic Neuropathy and the Suggested Measures |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T06%3A01%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Etiological%20Aspects%20for%20the%20Occurrence%20of%20Diabetic%20Neuropathy%20and%20the%20Suggested%20Measures&rft.jtitle=Neurophysiology%20(New%20York)&rft.au=Grover,%20M.&rft.date=2020-03-01&rft.volume=52&rft.issue=2&rft.spage=159&rft.epage=168&rft.pages=159-168&rft.issn=0090-2977&rft.eissn=1573-9007&rft_id=info:doi/10.1007/s11062-020-09865-2&rft_dat=%3Cgale_proqu%3EA640620813%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2450779271&rft_id=info:pmid/&rft_galeid=A640620813&rfr_iscdi=true |